Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
megestrol acetate + tamoxifen
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination hormonal therapy regimen consisting of alternating courses of megestrol acetate and tamoxifen. This regimen is primarily used for treating endometrial cancer, particularly recurrent or advanced disease. The standard dosing involves megestrol acetate 80 mg twice daily for 3 weeks alternating with tamoxifen 20 mg twice daily for 3 weeks.
02
Targets
ER (Estrogen receptor)PR (Progesterone receptor)
Beyond the preview
Go deeper on megestrol acetate + tamoxifen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on megestrol acetate + tamoxifen.